Lv1
68 积分 2024-07-23 加入
Overcoming therapy resistance in EGFR-mutant lung cancer
1个月前
已完结
MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies
2个月前
已完结
Accelerating scientific discovery with Co-Scientist
3个月前
已完结
Small cell lung cancer
4个月前
已完结
New approach methodologies for drug discovery
4个月前
已完结
Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas
4个月前
已完结
Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas
4个月前
已完结
Applications of High-Throughput DNA Sequencing to Single-Domain Antibody Discovery and Engineering
5个月前
已完结
LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
5个月前
已完结
Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA
7个月前
已完结
皖公网安备34019202002308
